Physician profile
Rodney T Smith
NPI 1215931191
$4,111.77
in general payments reported to CMS, 2019-2025
24 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $188 · 2021: $352 · 2022: $605 · 2023: $590 · 2024: $1,145 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Education: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.73 |
| Education | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $515.69 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $468.17 | 2019-2024 | Velphoro, Korsuva |
| Akebia Therapeutics INC | $454.58 | 2019-2025 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $342.91 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $336.51 | 2019-2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.52 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $308.80 | 2019-2024 | Rayaldee |
| Amgen INC. | $296.56 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $150.64 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $134.87 | 2023-2025 | Tarpeyo |
| Lilly USA, LLC | $121.08 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $98.34 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Aurinia Pharma U.S., INC. | $98.16 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $77.13 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $63.13 | 2024 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.50 | 2025 | |
| Alexion Pharmaceuticals, INC. | $52.63 | 2019-2022 | |
| Novo Nordisk INC | $50.65 | 2025 | Rybelsus, Ozempic |
| Travere Therapeutics, INC. | $35.77 | 2021-2025 | |
| Horizon Therapeutics Plc | $33.82 | 2023 | Krystexxa |
| Vantive US Healthcare LLC | $26.23 | 2025 | Renal - Acute |
| Cormedix INC. | $23.45 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $19.70 | 2025 | |
| Shire North American Group INC | $16.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.